Promatix Unveils 'Smart Bomb' ADCs to Unlock New Cancer Targets

LONDON, UK – April 21, 2026 – A UK-based biotech firm has presented a groundbreaking approach to cancer therapy that could dramatically expand the number of treatable tumours while significantly improving drug safety. At the American Association for Cancer Research (AACR) Annual Meeting 2026, Promatix Biosciences unveiled data on its proprietary platform, which uses a combination of deep proteomics and computational modeling to design highly selective “logic-gated” cancer drugs.

The technology addresses one of the most significant bottlenecks in modern oncology: the scarcity of truly cancer-specific targets for antibody-drug conjugates (ADCs), a class of potent therapies often described as biological smart bombs. By creating bispecific ADCs that require two separate signals to activate, Promatix aims to create a new generation of treatments that are not only more effective but also far kinder to the patient’s body.

Redefining ADC Precision with 'AND-Gate' Logic

Antibody-drug conjugates have long been heralded as a major advance in cancer treatment. They work by linking a highly potent chemotherapy agent to a monoclonal antibody, which is designed to seek out and bind to a specific protein, or antigen, on the surface of cancer cells. In theory, this allows the toxic payload to be delivered directly to the tumour, sparing healthy tissue. In practice, however, many of these target antigens are also present at low levels on healthy cells, leading to “on-target, off-tumour” toxicity that can cause severe side effects and limit the drug’s effectiveness.

Promatix's platform is engineered to solve this fundamental problem. Instead of relying on a single target, its approach is based on a dual-antigen, “AND-gate” system. This means the company’s bispecific ADCs will only bind strongly and release their cancer-killing payload when both of its target antigens are present on the same cell—a condition far more likely to be unique to a tumour. This dual-key requirement dramatically increases the precision of the attack.

“Across the ADC field, target selection is increasingly recognized as the critical bottleneck for achieving meaningful improvements in efficacy and safety,” said Dr. Michael Hunter, CEO and Co-Founder of Promatix, in a statement released during the conference. “Our integrated platform is designed to overcome this limitation through a systematic, data-driven approach to identifying complementary antigen pairs. In ADC development, we believe success will be determined by better targets, which will ultimately lead to better drugs.”

The engine behind this innovation is the company's integrated TxPro + CipherPro platform. TxPro is a vast, proprietary proteomics database containing detailed information on the expression of surface proteins across a wide range of tumours and normal tissues. The CipherPro computational framework then systematically mines this data, using Boolean logic to predict thousands of potential antigen pairs that could serve as the basis for a highly selective AND-gate bispecific ADC.

Unlocking a Universe of Untapped Cancer Targets

The data presented by Promatix at AACR 2026 paints a stark picture of the current limitations and the vast potential of its new approach. The company's analysis of its TxPro database, covering 2,768 surface proteins, revealed that truly tumour-selective monospecific targets are exceptionally rare. After filtering for sufficient expression on cancer cells, only 24 proteins showed a strong differential between tumour and normal tissue—a tiny pool from which to develop an entire class of drugs.

Strikingly, the company noted that many targets used in currently approved ADCs do not meet these stringent selectivity criteria, underscoring the inherent safety challenges that developers face. In contrast, by applying its CipherPro logic-gated modeling, Promatix was able to expand this limited landscape exponentially. Using a selectivity threshold of greater than 10-fold, the platform identified an astonishing 2,164 potential bispecific combinations, a nearly 100-fold increase over the monospecific options.

This expansion of the targetable universe is a significant development for the entire field. The current clinical landscape for bispecifics has shown limited target novelty, often relying on established and well-trodden antigens like EGFR and MET. Promatix’s ability to systematically identify novel, complementary pairs could fuel a new wave of ADC development, enabling therapies for cancers that have so far remained untargetable.

A New Front in the War on Colorectal Cancer

Beyond theoretical modeling, Promatix provided compelling evidence that its platform can translate computational predictions into biologically actionable therapies. The company presented preclinical data on its lead programme, PBS293, a bispecific ADC targeting the antigen pair EGFR × EphA2 for the treatment of metastatic colorectal cancer (mCRC).

The platform identified this pair based on its ideal expression pattern: minimal co-expression in healthy tissues but strong co-expression in colorectal tumours. This prediction was then experimentally validated using immunofluorescence staining on patient tumour biopsies and flow cytometry on patient-derived cancer models.

The clinical implications for mCRC are profound. A significant portion of patients, particularly those with RAS/BRAF gene mutations or right-sided tumours, do not respond to existing EGFR-targeting drugs like cetuximab. Promatix asserts that PBS293 is designed to be effective in these very patient populations, potentially offering a new lifeline where current therapies fail.

“Our data demonstrate that logic-gated bispecific discovery provides a viable and scalable path toward safer and more effective therapies across many cancer indications,” stated Dr. Roy Pettipher, Chief Scientific Officer of Promatix. “Importantly, this approach has already been used to identify a promising ADC candidate, our lead programme, PBS293... demonstrating how predictive discovery can translate into actionable therapeutic programmes.”

Navigating a Competitive and Evolving Landscape

Promatix is not alone in recognizing the need for smarter cancer drugs. The AACR 2026 meeting buzzed with presentations on next-generation ADCs, with several companies showcasing their own bispecific, dual-payload, or conditionally activated platforms. The emergence of multiple players in the “logic-gated” space validates the scientific premise and signals a broader industry pivot towards enhancing tumour selectivity.

While the concept is powerful, the path from a promising preclinical candidate to an approved drug is long and fraught with challenges. The complexity of designing, engineering, and manufacturing these sophisticated bispecific molecules is considerably higher than for traditional antibodies. Furthermore, the true test will come in clinical trials, where the platform’s predictive power must translate into a clear safety and efficacy benefit for patients in the complex environment of the human body.

Nonetheless, the systematic, data-first strategy presented by Promatix marks a departure from more traditional, trial-and-error drug discovery methods. By leveraging massive datasets and computational power to identify the most promising targets from the outset, this approach has the potential to de-risk development and accelerate the journey of novel cancer therapies to the clinic. For patients and clinicians awaiting the next breakthrough, this data-driven evolution of targeted therapy represents a significant and promising step forward.